InVivo Therapeutics Announces Stanford Medicine as New Site for INSPIRE Study


CAMBRIDGE, Mass. (July 12, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Stanford Medicine in Stanford, CA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Atman Desai, MD,  has been named Principal Investigator at the site. Dr. Desai is a Director of Neurosurgical Spinal Oncology and Clinical Assistant Professor of Neurosurgery at Stanford University Medical Center.

Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to welcome one of the most recognized hospitals in the world to the INSPIRE Study.  We look forward to working with Stanford Medicine and Dr. Desai, especially given Dr. Desai’s expertise in spinal cord injury treatment.”

There are now 34 clinical sites participating in the clinical study:

  • Allegheny General Hospital, Pittsburgh, PA
  • Banner University Medical Center, Tucson, AZ
  • Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, MO
  • Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix, AZ
  • Ben Taub Hospital/Baylor College of Medicine, Houston, TX
  • Beth Israel Deaconess Medical Center, Boston, MA
  • Brigham and Women’s Hospital, Boston, MA
  • Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte, NC
  • Cooper Neurological Institute, Camden, NJ
  • Foothills Medical Centre, Calgary, Alberta, Canada
  • Goodman Campbell Brain and Spine/Indiana University Health Neuroscience Center, Indianapolis, IN
  • Hospital of the University of Pennsylvania, Philadelphia, PA
  • James Cook University Hospital, Middlesbrough, United Kingdom
  • Keck Hospital of University of Southern California, Los Angeles, CA
  • Medical College of Wisconsin/Froedtert Hospital, Milwaukee, WI
  • Mount Sinai Hospital, New York, NY
  • Northwestern Medicine, Chicago, IL
  • Oregon Health & Science University, Portland, OR
  • Rhode Island Hospital, Providence, RI
  • Rutgers New Jersey Medical School, Newark, NJ
  • Stanford Medicine, Stanford, CA
  • St. Michael’s Hospital, Toronto, Ontario, Canada
  • Thomas Jefferson University Hospital, Philadelphia, PA
  • Toronto Western Hospital, Toronto, Ontario, Canada
  • UC Health Memorial Hospital, Colorado Springs, CO
  • University of California, Davis Medical Center, Sacramento, CA
  • University of California, San Diego Medical Center, San Diego, CA
  • University of Iowa Hospitals and Clinics, Iowa City, IA
  • University of Kansas Medical Center, Kansas City, KS
  • University of Louisville Hospital, Louisville, KY
  • University of New Mexico Hospital, Albuquerque, NM
  • University of Pittsburgh Medical Center Presbyterian, Pittsburgh, PA
  • University of Virginia Health System, Charlottesville, VA
  • Vidant Medical Center, Greenville, NC

For more information, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110

About the Neuro-Spinal Scaffold Implant
Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural repair within and around the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury. For more information on the cervical study, refer to https://clinicaltrials.gov/ct2/show/study/NCT03105882.

About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

 

Read More